passiv
immun
base
administr
serum
convalescentvaccin
human
donor
anim
attempt
prevent
control
infect
whilst
vaccin
requir
time
induc
immun
depend
host
abil
mount
immun
respons
passiv
immun
provid
immedi
protect
theoret
independ
recipi
immun
statu
follow
develop
antidiphtheria
serum
behr
kitasato
earli
immun
sera
convalesc
human
use
prevent
treat
rang
viral
diseas
includ
measl
pandem
flu
varicellazost
viru
bolivian
hemorrhag
fever
argentin
hemorrhag
fever
well
ebola
lassa
hemorrhag
fever
moreov
earliest
attempt
cure
veterinari
diseas
involv
passiv
immun
serum
recov
anim
describ
semin
attempt
cure
rinderpest
today
sever
pool
antivir
immunoglobulin
product
still
avail
us
market
includ
hyperimmun
immunoglobulin
prepar
rabi
viru
cytomegaloviru
hepat
b
c
virus
vaccinia
viru
varicellazost
viru
respiratori
syncyti
viru
rsv
west
nile
viru
common
disadvantag
polyclon
prepar
mani
constitu
virusspecif
antibodi
nonneutr
moreov
polyclon
sera
screen
treat
due
risk
relat
use
blood
product
problem
associ
use
polyclon
sera
might
also
includ
batchtobatch
variat
difficulti
obtain
immun
donor
altern
polyclon
antibodi
prepar
offer
develop
monoclon
antibodi
mab
milstein
develop
hybridoma
medic
research
council
molecular
biolog
cambridg
uk
sinc
technolog
gener
engin
mab
greatli
improv
industri
mab
product
result
larg
number
antivir
mab
develop
preclin
clinic
studi
fulli
human
mab
fig
minim
immunogen
gener
use
method
phage
display
purifi
envelop
glycoprotein
either
monomer
oligomer
form
viral
particl
two
type
antigen
commonli
use
bait
pan
antibodi
librari
antibodi
librari
either
viral
antigen
obtain
convalesc
immun
patient
anim
first
antivir
mab
approv
us
food
drug
administr
fda
palivizumab
synagi
medimmun
human
antibodi
confer
rsv
prophylaxi
high
risk
infant
prior
palivizumab
prophylaxi
rsv
diseas
depend
polyclon
serum
prepar
call
respigam
rsvigiv
polyclon
prepar
show
rel
low
specif
activ
dose
requir
applic
rel
larg
volum
antibodi
low
weight
infant
greater
potenc
palivizumab
reduc
volum
requir
deliv
therapeut
dose
infant
improv
rsv
treatment
avoid
side
effect
pool
serum
specif
antibodi
titer
identifi
correl
protect
variou
viral
infect
antibodi
oper
variou
mechan
mediat
either
variabl
constant
region
highli
select
bind
specif
epitop
target
antigen
function
crucial
properti
mediat
antibodi
variabl
domain
antibodi
constant
domain
includ
fc
region
perform
import
function
includ
antibodydepend
cellular
cytotox
adcc
antibodydepend
cellular
phagocytosi
adcp
complementdepend
cytotox
cdc
adcc
adcp
mediat
fcg
receptor
cdc
mediat
complement
cascad
protein
anoth
function
fc
region
extens
antibodi
halflif
day
human
igg
interact
neonat
fc
receptor
fcrn
antibodi
interfer
viru
entri
cell
variou
mechan
one
mechan
inhibit
viru
attach
cell
surfac
receptor
achiev
antibodi
bind
viral
spike
therebi
interf
abil
bind
cellular
receptor
effect
achiev
antibodi
target
receptor
coreceptor
therebi
make
bind
site
virus
unavail
anoth
mechan
postbindingprefus
neutral
interfer
requir
conform
chang
cell
membran
endosom
membran
antibodi
target
nonreceptor
bind
region
addit
mechan
viru
neutral
includ
antibodymedi
crosslink
virion
result
immobil
agglutin
inhibit
releas
progeni
viru
observ
eg
antibodi
influenza
viru
gener
viru
neutral
consid
occur
suffici
number
epitop
viral
surfac
occupi
antibodi
occup
model
sometim
refer
multihit
model
propos
obtain
suffici
antibodi
densiti
virion
critic
factor
neutral
lead
inhibit
attach
cellular
receptor
interfer
p
e
r
p
l
k
endosom
plasma
membran
fusion
process
altern
model
neutral
critic
bind
site
model
compat
singleor
multihit
theori
neutral
accord
model
neutral
depend
target
essenti
bind
site
less
depend
obtain
high
antibodi
densiti
viral
surfac
addit
abil
directli
interfer
viru
entri
cell
antibodi
counteract
viral
infect
mean
fc
effector
function
extent
effector
function
contribut
protect
appear
specif
differ
virus
demonstr
neutral
mab
engin
activ
complement
protect
wildtyp
antibodi
howev
complement
fcrn
neonat
fc
receptor
abolish
antibodi
show
reduc
vivo
protect
capac
observ
point
import
role
adcc
hiv
neutral
fc
effector
function
seem
requir
neutral
sever
virus
eg
antibodi
fc
region
associ
effector
function
necessari
neutral
rabi
viru
equin
sera
rabi
postexposureprophylaxi
pep
human
routin
consist
f
ab
fragment
prepar
pepsin
digest
devoid
fc
region
case
antibodi
may
also
act
immunomodul
certain
antivir
mab
shown
vaccinelik
effect
mice
infect
murin
retroviru
subject
short
immunotherapi
neutral
mab
isotyp
remain
healthi
mount
longlast
protect
antivir
immun
strong
humor
cellular
immun
respons
endogen
antivir
antibodi
gener
mabtreat
mice
allow
contain
viral
propag
enhanc
memori
cellular
respons
disappear
inject
mab
administr
mab
permit
develop
longlast
endogen
antivir
immun
point
import
role
infectedcellantibodi
immun
complex
longterm
protect
mediat
short
passiv
immunotherapi
effect
immunoprophylaxi
antigen
variabl
circul
viral
strain
potenti
emerg
viral
escap
mutant
need
consid
consider
special
import
case
influenza
virus
antigen
drift
antigen
shift
occur
natur
case
hiv
format
differ
quasispeci
mani
differ
viru
variant
drive
immun
evas
rna
virus
possess
rna
polymeras
devoid
proofread
repair
capabl
may
result
emerg
resist
mutant
select
pressur
mab
administr
escap
mutant
gener
vitro
select
pressur
antibodi
observ
eg
mab
chikungunya
viru
intriguingli
highthroughput
sequenc
also
detect
mutat
residu
associ
chikungunya
viral
escap
sequenc
deriv
viru
treat
nonspecif
antibodi
although
proport
extrem
low
total
nucleotid
posit
suggest
minor
preexist
viral
quasispeci
amplifi
select
pressur
addit
isol
viral
escap
mutant
vitro
also
isol
vivo
eg
influenza
escap
mutant
isol
lung
mice
receiv
mab
moreov
resist
rsv
variant
could
isol
patient
receiv
palivizumab
nucleotid
sequenc
analysi
rsv
isol
collect
directli
infant
receiv
palivizumab
still
develop
acut
lower
tract
respiratori
infect
reveal
specif
mutat
rsv
fusion
protein
allow
viru
escap
neutral
second
gener
affinitymatur
variant
palivizumab
term
motavizumab
recent
develop
investig
larg
compar
phase
clinic
studi
two
prepar
similar
palivizumab
treatment
resist
rsv
variant
contain
certain
sequenc
chang
rsv
envelop
protein
gener
either
vitro
collect
rsv
breakthrough
patient
receiv
motavizumab
emerg
viral
escap
accompani
alter
viral
fit
affect
viru
growth
vitro
infect
host
mutat
may
render
viral
escap
mutant
resist
specif
mab
alter
growth
infect
may
render
viru
attenu
clear
host
immun
system
broad
coverag
differ
strain
well
prevent
viral
escap
mutant
import
consider
develop
passiv
immunotherapi
variou
combin
mab
develop
assess
tabl
mab
select
inclus
cocktail
base
specif
function
complement
regard
breadth
specif
compet
antigen
bind
cocktail
mab
might
requir
target
epitop
singl
mab
conserv
strain
viru
especi
case
human
infect
emerg
heterogen
pool
circul
variou
anim
reservoir
exampl
genu
lyssaviru
compris
numer
differ
close
relat
viru
strain
circul
rang
differ
host
order
carnivora
dog
wildlif
chiroptera
bat
follow
sever
exposur
rabid
anim
prompt
administr
rabi
pep
includ
administr
human
equin
rabi
immunoglobulin
hrig
erig
respect
prevent
develop
rabi
death
previous
unvaccin
victim
crucellsanofi
develop
cocktail
two
potent
mab
replac
hrig
erig
pep
cocktail
design
appli
two
main
criteria
first
mab
cover
wide
rang
viral
variant
target
distinct
nonoverlap
epitop
prefer
compet
antigen
bind
secondli
vitrogener
mabresist
escap
mutant
select
use
one
antibodi
neutral
nonselect
mab
cocktail
vice
versa
crucel
mab
cocktail
undergo
clinic
trial
exemplifi
issu
viral
heterogen
emerg
resist
viru
variant
overcom
combin
two
mab
addit
antirabi
mab
combin
mab
develop
sever
viral
diseas
includ
influenza
instanc
two
mab
target
influenza
hemagglutinin
molecul
develop
mab
shown
target
differ
epitop
demonstr
reciproc
coverag
escap
mutant
combin
two
mab
show
broad
coverag
differ
clade
escap
variant
detect
therapi
similarli
combin
two
noncompet
human
mab
sarscoronaviru
sarscov
develop
combin
potenti
control
immun
escap
extend
breadth
protect
may
allow
lower
total
antibodi
dose
administ
passiv
immun
prophylaxi
sarscov
infect
synerg
neutral
mab
report
sarscov
also
observ
eg
combin
two
three
four
mab
direct
differ
epitop
envelop
glycoprotein
lead
twoto
tenfold
increas
neutral
titer
consid
biolog
requir
antivir
mab
antibodi
valenc
import
factor
observ
varicellazost
viru
hiv
rabi
viru
bival
antibodi
bind
mediat
crosslink
virion
result
immobil
agglutin
shown
certain
epitop
eg
herp
simplex
viru
hsv
effici
target
bival
antibodi
format
fullsiz
mab
f
ab
use
monoval
antibodi
format
scfv
f
ab
sever
diminish
neutral
hsv
neutral
f
ab
fragment
could
restor
crosslinkag
f
ab
use
igg
react
murin
f
ab
fragment
observ
demonstr
neutral
mab
depend
crosslinkag
glycoprotein
b
gb
trimer
immobil
gb
trimer
inhibit
activ
fusogen
signal
consequ
bival
mab
deriv
exhibit
adequ
vitro
neutral
activ
natur
multival
achiev
dimeris
multimeris
immunoglobulin
subunit
result
polymer
secretori
iga
igm
antibodi
whilst
igm
antibodi
gener
consid
low
bind
affin
import
primari
immun
respons
secretori
iga
siga
predomin
protect
antibodi
mucos
secret
somewhat
complic
assembl
requir
natur
requir
plasma
cell
produc
dimer
iga
epitheli
cell
contribut
secretori
compon
result
slow
progress
develop
mab
although
express
possibl
mammalian
cell
express
system
approach
difficult
scaleup
howev
recombin
secretori
antibodi
product
also
describ
plant
system
offer
hope
siga
base
prophylaxi
mucos
infect
futur
gener
bival
antibodi
bind
contribut
neutral
virus
express
high
densiti
surfac
spike
rsv
influenza
viru
contrast
hiv
limit
number
surfac
spike
propos
low
densiti
trimer
render
mab
less
effici
viral
neutral
interf
bival
bind
viru
matur
hiv
particl
express
randomli
distribut
viral
spike
would
space
far
apart
bival
antibodi
bridg
howev
multival
bind
could
theoret
still
achiev
alter
antibodi
geometri
e
g
dimer
form
mab
demonstr
substanti
increas
neutral
potenc
exampl
multival
mab
increas
potenc
compar
origin
igg
includ
polymer
iga
igm
version
antihiv
mab
altern
homotyp
bival
bind
heterotyp
bival
bispecif
bind
eg
design
scfvfc
molecul
immunoadhesin
bind
bival
virtu
one
scfv
arm
target
second
arm
target
subunit
fig
special
geometri
immunoadhesin
shown
overcom
lack
bival
bind
hiv
surfac
spike
anoth
studi
investig
sever
novel
tetraval
bispecif
antibodi
deriv
simultan
target
two
differ
epitop
hiv
coreceptor
molecul
base
morrisontyp
bispecif
antibodi
whole
igg
connect
scfv
via
flexibl
linker
fig
bispecif
mab
maintain
bind
activ
toward
individu
epitop
abl
simultan
block
two
dock
site
hiv
strain
show
increas
antivir
activ
compar
parent
monospecif
antibodi
interestingli
one
prototyp
tetraval
antibodi
antivir
activ
viru
strain
resist
singl
parent
antibodi
summari
increas
valenc
bispecif
translat
enhanc
antivir
potenc
increas
threshold
antivir
resist
multispecif
antibodi
also
gener
fuse
small
molecul
antibodi
eg
construct
singl
multimer
recombin
protein
combin
function
activ
antihiv
mab
small
microbicid
protein
cyanovirin
fig
importantli
two
molecul
compet
antigen
bind
recogn
conform
amino
acid
epitop
hiv
wherea
cyanovirin
bind
glycan
epitop
strategi
similar
bispecif
construct
also
appli
molecul
eg
bifunct
hiv
fusion
inhibitor
bffi
molecul
gener
link
either
antibodi
small
fusion
inhibitor
multimer
molecul
target
murin
cytomegalovirusinfect
cell
construct
link
cytomegalovirusspecif
antibodi
cellular
toxin
deglycosyl
ricin
chain
antibodi
engin
antibodi
variabl
domain
engin
small
fragment
tabl
includ
scfv
f
ab
molecul
requir
product
costli
eukaryot
express
system
sever
small
antibodi
fragment
investig
regard
antivir
activ
includ
camelid
vhh
domain
serum
camel
dromedari
llama
contain
uniqu
type
antibodi
devoid
antibodi
light
chain
camelid
heavychain
antibodi
attract
interest
recogn
antigen
via
singl
vhh
domain
express
inexpens
bacteri
yeast
express
system
vhh
develop
sever
infecti
diseas
eg
potent
entri
inhibitor
addit
heavi
chain
immunoglobulin
camelida
famili
singl
domain
antibodi
discov
cartilagin
fish
shark
possibl
ray
shark
antibodi
also
call
ig
new
antigen
receptor
ignar
develop
hepat
b
viru
zair
ebolaviru
engin
effort
also
aim
modifiy
antibodi
variabl
constant
domain
eg
identif
palivizumab
synagi
medimmuneabbott
follow
develop
secondgener
version
motavizumab
medimmun
affin
matur
complementarydetermin
region
cdr
moreov
mab
medimmun
thirdgener
version
motavizumab
current
investig
clinic
trial
contain
engin
fc
domain
longer
halflif
optim
fc
effector
function
focu
antibodi
engin
two
main
approach
sitespecif
mutagenesi
deglycosyl
appli
engin
antivir
antibodi
greatli
enhanc
bind
fcriiia
andor
fcriia
exampl
panel
eleven
variant
antihiv
mab
broad
rang
affin
fcriia
fcriiia
investig
variant
increas
affin
either
main
activ
receptor
fcriia
fcriiia
also
demonstr
increas
viral
inhibit
compar
origin
antibodi
certain
viral
diseas
applic
specif
modif
reduc
elimin
specif
fc
effector
function
may
desir
eg
alter
fc
region
explor
way
reduc
elimin
antibodydepend
enhanc
ade
infect
ade
wellrecogn
phenomenon
observ
variou
infect
includ
numer
flaviviru
infect
eg
west
nile
viru
dengu
viru
activ
immun
passiv
transfer
antibodi
shown
mediat
phenomenon
result
increas
uptak
viru
presenc
neutral
antibodi
virusspecif
antibodi
enhanc
viral
entri
case
replic
monocytesmacrophag
granulocyt
cell
interact
fcg
andor
complement
receptor
ade
propos
mechan
respons
dengu
hemorrhag
fever
dengu
shock
syndrom
two
clinic
condit
frequent
seen
patient
infect
second
heterotrop
infect
infant
matern
transfer
antidengu
antibodi
dengu
viru
four
serotyp
exist
gener
antibodi
follow
exposur
one
serotyp
may
affect
respons
repeat
exposur
altern
serotyp
experiment
passiv
transfer
high
dose
serotypespecif
antibodi
enabl
elimin
viremia
lower
dose
antibodi
crossreact
polyclon
monoclon
antibodi
may
caus
enhanc
diseas
vivo
contrast
genet
engin
mab
variant
eg
bind
fcg
receptor
exhibit
prophylact
therapeut
efficaci
adeinduc
lethal
challeng
recent
identif
human
mab
broadli
neutral
differ
hiv
strain
may
allow
revers
engin
potent
vaccin
human
serolog
respons
infect
target
intern
viral
surfac
protein
antibodi
target
hiv
envelop
spike
achiev
viral
neutral
conform
flexibl
consid
main
obstacl
develop
vaccin
besid
sequenc
variabl
glycan
shield
howev
observ
mab
target
certain
epitop
protect
suggest
vaccin
elicit
antibodi
could
similar
effect
broadli
neutral
mab
direct
either
effort
focus
design
epitop
mimic
order
direct
humor
respons
toward
neutral
epitop
vaccin
similar
strategi
might
also
appli
develop
potent
vaccin
influenza
viru
follow
recent
identif
broadli
neutral
human
mab
v
h
germlin
heavi
chain
mab
shown
broadli
neutral
mani
influenza
group
virus
crystal
structur
mab
complex
hemagglutinin
reveal
highli
conserv
epitop
ha
stalk
subsequ
studi
identifi
human
mab
show
broad
neutral
activ
group
virus
target
conserv
epitop
ha
stalk
distinct
epitop
recogn
v
h
group
antibodi
mab
target
group
virus
potenti
complementari
may
henc
open
prospect
develop
univers
influenza
vaccin
oppos
current
vaccin
restrict
circul
season
strain
applic
antivir
mab
may
also
includ
infect
central
nervou
system
cn
sever
mab
shown
promis
clear
establish
neurolog
diseas
includ
west
nile
viru
hendra
viru
infect
howev
use
antibodi
neurolog
infect
may
frequent
limit
due
presenc
bloodbrainbarri
bbb
especi
infect
like
rabi
bbb
remain
larg
intact
patient
clinic
rabi
respond
pep
advanc
deliv
therapeut
mab
specif
cn
explor
polyclon
antibodi
increasingli
replac
mab
eg
hepat
b
immunoglobulin
hbig
varicellazost
immunoglobulin
vzig
rabi
immunoglobulin
rig
rig
part
essenti
medicin
list
adult
children
use
mab
could
help
overcom
current
insuffici
suppli
antiserum
across
develop
world
therebi
contribut
meet
vision
unit
nation
millennium
declar
importantli
though
cost
mab
product
choic
express
system
need
care
consid
make
candid
prepar
wide
avail
afford
rel
high
expens
usual
shortliv
protect
mab
due
limit
halflif
may
imped
widespread
applic
diseas
small
molecul
drug
vaccin
avail
cost
monthli
dose
palivizumab
rsv
prevent
british
pound
per
patient
indic
high
expens
mab
develop
product
storag
prohibit
access
antivir
mab
may
restrict
especi
lowincom
countri
effort
made
develop
inexpens
product
platform
amen
transfer
develop
world
particular
use
transgen
plant
rais
hope
sever
mab
prepar
may
becom
wide
avail
r
e
f
e
r
e
n
c
e
p
e
n
n
c
w
